Clincosm LogoSign in Get a demo

Study of Cannabidiol for Drug-Resistant Epilepsies

Sponsor
Eric Marsh, MD (Other)
Overall Status
No longer available
CT.gov ID
NCT03014440
Collaborator
University of Pittsburgh (Other), Geisinger Clinic (Other)

Study Details

Study Description

Brief Summary

The purpose of this study is to determine if cannabidiol is safe and effective at different doses as an additional treatment for pediatric drug-resistant epilepsy. Pure cannabidiol has potentially therapeutic properties, such as anti-convulsant effects, that may reduce seizure frequency. There are only a few open label studies that have demonstrated the safety and tolerance of cannabiodiol in both adult and pediatric epileptic populations--these studies were performed either retrospectively or with varying cannabidiol preparations. There are no well-documented studies and completely analyzed data for pediatric epileptic patients.

Condition or Disease Intervention/Treatment Phase

Study Design

Study Type:
Expanded Access
Official Title:
A Phase 1/2, Safety, Tolerability, and Dose-Finding Study of Cannabidiol for Drug-Resistant Epilepsies

Outcome Measures

Primary Outcome Measures

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    1 Year to 20 Years
    Sexes Eligible for Study:
    All
    Inclusion Criteria:

    1. Ages between 1 year old and 20 years old, male or female at the first visit, Week -4 (at time informed consent form is signed)

    2. Documentation of a diagnosis of drug-resistant epilepsy as proven by and documented with medical records and/or the following clinical features (must have all 3 of the following):

    3. Failure to control seizures despite appropriate trial of 3 or more AEDs at therapeutic doses

    4. An intractable childhood epilepsy including, Dravet Syndrome or Lennox-Gastaut Syndrome

    5. Must report at least 3 countable (non-countable seizures includes absence and myoclonic) seizures per month

    6. Between 1-3 baseline AEDs . Vagus nerve stimulator (VNS), ketogenic diet, and modified Atkins diet do not count towards this limit.

    7. VNS must be on stable settings for a minimum of 3 months.

    8. If on the ketogenic diet, must be on stable ratio for a minimum of 3 months.

    Exclusion Criteria:

    1. Epilepsies associated with neurodegenerative diseases, including neuronal ceroidolipofuscinosis, progressive myoclonus epilepsies, Rasmussen encephalitis, and tumors

    2. Epilepsies associated with an inborn error of metabolism, including mitochondrial disorders

    3. Felbatol initiated within the past 12 months

    4. Use of any Cannabis-related product (including hemp oil) in the past 12 months as assessed by parental questioning.

    5. Laboratory values on comprehensive metabolic panel (CMP) and complete blood count (CBC) testing that are Class 3 or higher according to the CTCAE v4.0.

    6. Positive pregnancy test.

    Contacts and Locations

    Locations

    No locations specified.

    Sponsors and Collaborators

    • Eric Marsh, MD
    • University of Pittsburgh
    • Geisinger Clinic

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Eric Marsh, MD, Assistant Professor of Pediatrics and Neurology, Children's Hospital of Philadelphia
    ClinicalTrials.gov Identifier:
    NCT03014440
    Other Study ID Numbers:
    • 13-010562
    First Posted:
    Jan 9, 2017
    Last Update Posted:
    Apr 4, 2017
    Last Verified:
    Mar 1, 2017
    Additional relevant MeSH terms:
    Epilepsy
    Drug Resistant Epilepsy
    Cannabidiol

    Study Results

    No Results Posted as of Apr 4, 2017